img

Global VEGF Inhibitor Drugs Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global VEGF Inhibitor Drugs Market Insights, Forecast to 2034

Vascular endothelial growth factor (VEGF) is an angiogenic factor responsible for the formation of blood vessels either from already existing blood vessels or from vascular endothelial cells.
Market Analysis and InsightsGlobal VEGF Inhibitor Drugs Market
Global VEGF Inhibitor Drugs market is expected to reach to US$ 8961 million in 2024, with a positive growth of %, compared with US$ 8271 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, VEGF Inhibitor Drugs industry is evaluated to reach US$ 14460 million in 2029. The CAGR will be 8.3% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global VEGF Inhibitor Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global VEGF Inhibitor Drugs market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Pfizer
Novartis AG
GlaxoSmithKline plc
Sanofi
AstraZeneca plc
Bristol-Myers-Squibb Company
Genentech, Inc. (Roche)
Merck & Co., Inc.
Bayer AG
Eli Lilly & Company
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others

Segment by Application


Oncology
Ophthalmology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, VEGF Inhibitor Drugs introduction, etc. VEGF Inhibitor Drugs Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of VEGF Inhibitor Drugs
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global VEGF Inhibitor Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Tyrosine Kinase Inhibitors
1.2.3 Monoclonal Antibodies
1.2.4 Others
1.3 Market by Application
1.3.1 Global VEGF Inhibitor Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Oncology
1.3.3 Ophthalmology
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global VEGF Inhibitor Drugs Market Perspective (2018-2029)
2.2 Global VEGF Inhibitor Drugs Growth Trends by Region
2.2.1 VEGF Inhibitor Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 VEGF Inhibitor Drugs Historic Market Size by Region (2018-2024)
2.2.3 VEGF Inhibitor Drugs Forecasted Market Size by Region (2024-2029)
2.3 VEGF Inhibitor Drugs Market Dynamics
2.3.1 VEGF Inhibitor Drugs Industry Trends
2.3.2 VEGF Inhibitor Drugs Market Drivers
2.3.3 VEGF Inhibitor Drugs Market Challenges
2.3.4 VEGF Inhibitor Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue VEGF Inhibitor Drugs by Players
3.1.1 Global VEGF Inhibitor Drugs Revenue by Players (2018-2024)
3.1.2 Global VEGF Inhibitor Drugs Revenue Market Share by Players (2018-2024)
3.2 Global VEGF Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of VEGF Inhibitor Drugs, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global VEGF Inhibitor Drugs Market Concentration Ratio
3.4.1 Global VEGF Inhibitor Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by VEGF Inhibitor Drugs Revenue in 2022
3.5 Global Key Players of VEGF Inhibitor Drugs Head office and Area Served
3.6 Global Key Players of VEGF Inhibitor Drugs, Product and Application
3.7 Global Key Players of VEGF Inhibitor Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 VEGF Inhibitor Drugs Breakdown Data by Type
4.1 Global VEGF Inhibitor Drugs Historic Market Size by Type (2018-2024)
4.2 Global VEGF Inhibitor Drugs Forecasted Market Size by Type (2024-2029)
5 VEGF Inhibitor Drugs Breakdown Data by Application
5.1 Global VEGF Inhibitor Drugs Historic Market Size by Application (2018-2024)
5.2 Global VEGF Inhibitor Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America VEGF Inhibitor Drugs Market Size (2018-2029)
6.2 North America VEGF Inhibitor Drugs Market Size by Type
6.2.1 North America VEGF Inhibitor Drugs Market Size by Type (2018-2024)
6.2.2 North America VEGF Inhibitor Drugs Market Size by Type (2024-2029)
6.2.3 North America VEGF Inhibitor Drugs Market Share by Type (2018-2029)
6.3 North America VEGF Inhibitor Drugs Market Size by Application
6.3.1 North America VEGF Inhibitor Drugs Market Size by Application (2018-2024)
6.3.2 North America VEGF Inhibitor Drugs Market Size by Application (2024-2029)
6.3.3 North America VEGF Inhibitor Drugs Market Share by Application (2018-2029)
6.4 North America VEGF Inhibitor Drugs Market Size by Country
6.4.1 North America VEGF Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America VEGF Inhibitor Drugs Market Size by Country (2018-2024)
6.4.3 North America VEGF Inhibitor Drugs Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe VEGF Inhibitor Drugs Market Size (2018-2029)
7.2 Europe VEGF Inhibitor Drugs Market Size by Type
7.2.1 Europe VEGF Inhibitor Drugs Market Size by Type (2018-2024)
7.2.2 Europe VEGF Inhibitor Drugs Market Size by Type (2024-2029)
7.2.3 Europe VEGF Inhibitor Drugs Market Share by Type (2018-2029)
7.3 Europe VEGF Inhibitor Drugs Market Size by Application
7.3.1 Europe VEGF Inhibitor Drugs Market Size by Application (2018-2024)
7.3.2 Europe VEGF Inhibitor Drugs Market Size by Application (2024-2029)
7.3.3 Europe VEGF Inhibitor Drugs Market Share by Application (2018-2029)
7.4 Europe VEGF Inhibitor Drugs Market Size by Country
7.4.1 Europe VEGF Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe VEGF Inhibitor Drugs Market Size by Country (2018-2024)
7.4.3 Europe VEGF Inhibitor Drugs Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China VEGF Inhibitor Drugs Market Size (2018-2029)
8.2 China VEGF Inhibitor Drugs Market Size by Type
8.2.1 China VEGF Inhibitor Drugs Market Size by Type (2018-2024)
8.2.2 China VEGF Inhibitor Drugs Market Size by Type (2024-2029)
8.2.3 China VEGF Inhibitor Drugs Market Share by Type (2018-2029)
8.3 China VEGF Inhibitor Drugs Market Size by Application
8.3.1 China VEGF Inhibitor Drugs Market Size by Application (2018-2024)
8.3.2 China VEGF Inhibitor Drugs Market Size by Application (2024-2029)
8.3.3 China VEGF Inhibitor Drugs Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia VEGF Inhibitor Drugs Market Size (2018-2029)
9.2 Asia VEGF Inhibitor Drugs Market Size by Type
9.2.1 Asia VEGF Inhibitor Drugs Market Size by Type (2018-2024)
9.2.2 Asia VEGF Inhibitor Drugs Market Size by Type (2024-2029)
9.2.3 Asia VEGF Inhibitor Drugs Market Share by Type (2018-2029)
9.3 Asia VEGF Inhibitor Drugs Market Size by Application
9.3.1 Asia VEGF Inhibitor Drugs Market Size by Application (2018-2024)
9.3.2 Asia VEGF Inhibitor Drugs Market Size by Application (2024-2029)
9.3.3 Asia VEGF Inhibitor Drugs Market Share by Application (2018-2029)
9.4 Asia VEGF Inhibitor Drugs Market Size by Region
9.4.1 Asia VEGF Inhibitor Drugs Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia VEGF Inhibitor Drugs Market Size by Region (2018-2024)
9.4.3 Asia VEGF Inhibitor Drugs Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer VEGF Inhibitor Drugs Introduction
11.1.4 Pfizer Revenue in VEGF Inhibitor Drugs Business (2018-2024)
11.1.5 Pfizer Recent Developments
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG VEGF Inhibitor Drugs Introduction
11.2.4 Novartis AG Revenue in VEGF Inhibitor Drugs Business (2018-2024)
11.2.5 Novartis AG Recent Developments
11.3 GlaxoSmithKline plc
11.3.1 GlaxoSmithKline plc Company Details
11.3.2 GlaxoSmithKline plc Business Overview
11.3.3 GlaxoSmithKline plc VEGF Inhibitor Drugs Introduction
11.3.4 GlaxoSmithKline plc Revenue in VEGF Inhibitor Drugs Business (2018-2024)
11.3.5 GlaxoSmithKline plc Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi VEGF Inhibitor Drugs Introduction
11.4.4 Sanofi Revenue in VEGF Inhibitor Drugs Business (2018-2024)
11.4.5 Sanofi Recent Developments
11.5 AstraZeneca plc
11.5.1 AstraZeneca plc Company Details
11.5.2 AstraZeneca plc Business Overview
11.5.3 AstraZeneca plc VEGF Inhibitor Drugs Introduction
11.5.4 AstraZeneca plc Revenue in VEGF Inhibitor Drugs Business (2018-2024)
11.5.5 AstraZeneca plc Recent Developments
11.6 Bristol-Myers-Squibb Company
11.6.1 Bristol-Myers-Squibb Company Company Details
11.6.2 Bristol-Myers-Squibb Company Business Overview
11.6.3 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Introduction
11.6.4 Bristol-Myers-Squibb Company Revenue in VEGF Inhibitor Drugs Business (2018-2024)
11.6.5 Bristol-Myers-Squibb Company Recent Developments
11.7 Genentech, Inc. (Roche)
11.7.1 Genentech, Inc. (Roche) Company Details
11.7.2 Genentech, Inc. (Roche) Business Overview
11.7.3 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Introduction
11.7.4 Genentech, Inc. (Roche) Revenue in VEGF Inhibitor Drugs Business (2018-2024)
11.7.5 Genentech, Inc. (Roche) Recent Developments
11.8 Merck & Co., Inc.
11.8.1 Merck & Co., Inc. Company Details
11.8.2 Merck & Co., Inc. Business Overview
11.8.3 Merck & Co., Inc. VEGF Inhibitor Drugs Introduction
11.8.4 Merck & Co., Inc. Revenue in VEGF Inhibitor Drugs Business (2018-2024)
11.8.5 Merck & Co., Inc. Recent Developments
11.9 Bayer AG
11.9.1 Bayer AG Company Details
11.9.2 Bayer AG Business Overview
11.9.3 Bayer AG VEGF Inhibitor Drugs Introduction
11.9.4 Bayer AG Revenue in VEGF Inhibitor Drugs Business (2018-2024)
11.9.5 Bayer AG Recent Developments
11.10 Eli Lilly & Company
11.10.1 Eli Lilly & Company Company Details
11.10.2 Eli Lilly & Company Business Overview
11.10.3 Eli Lilly & Company VEGF Inhibitor Drugs Introduction
11.10.4 Eli Lilly & Company Revenue in VEGF Inhibitor Drugs Business (2018-2024)
11.10.5 Eli Lilly & Company Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global VEGF Inhibitor Drugs Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Tyrosine Kinase Inhibitors
Table 3. Key Players of Monoclonal Antibodies
Table 4. Key Players of Others
Table 5. Global VEGF Inhibitor Drugs Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 6. Global VEGF Inhibitor Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global VEGF Inhibitor Drugs Market Size by Region (2018-2024) & (US$ Million)
Table 8. Global VEGF Inhibitor Drugs Market Share by Region (2018-2024)
Table 9. Global VEGF Inhibitor Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global VEGF Inhibitor Drugs Market Share by Region (2024-2029)
Table 11. VEGF Inhibitor Drugs Market Trends
Table 12. VEGF Inhibitor Drugs Market Drivers
Table 13. VEGF Inhibitor Drugs Market Challenges
Table 14. VEGF Inhibitor Drugs Market Restraints
Table 15. Global VEGF Inhibitor Drugs Revenue by Players (2018-2024) & (US$ Million)
Table 16. Global VEGF Inhibitor Drugs Revenue Share by Players (2018-2024)
Table 17. Global Top VEGF Inhibitor Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Inhibitor Drugs as of 2022)
Table 18. Global VEGF Inhibitor Drugs Industry Ranking 2021 VS 2022 VS 2024
Table 19. Global 5 Largest Players Market Share by VEGF Inhibitor Drugs Revenue (CR5 and HHI) & (2018-2024)
Table 20. Global Key Players of VEGF Inhibitor Drugs, Headquarters and Area Served
Table 21. Global Key Players of VEGF Inhibitor Drugs, Product and Application
Table 22. Global Key Players of VEGF Inhibitor Drugs, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global VEGF Inhibitor Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 25. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2018-2024)
Table 26. Global VEGF Inhibitor Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2024-2029)
Table 28. Global VEGF Inhibitor Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 29. Global VEGF Inhibitor Drugs Revenue Share by Application (2018-2024)
Table 30. Global VEGF Inhibitor Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global VEGF Inhibitor Drugs Revenue Share by Application (2024-2029)
Table 32. North America VEGF Inhibitor Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 33. North America VEGF Inhibitor Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 34. North America VEGF Inhibitor Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 35. North America VEGF Inhibitor Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 36. North America VEGF Inhibitor Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. North America VEGF Inhibitor Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 38. North America VEGF Inhibitor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Europe VEGF Inhibitor Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 40. Europe VEGF Inhibitor Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 41. Europe VEGF Inhibitor Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 42. Europe VEGF Inhibitor Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 43. Europe VEGF Inhibitor Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Europe VEGF Inhibitor Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 45. Europe VEGF Inhibitor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 46. China VEGF Inhibitor Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 47. China VEGF Inhibitor Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 48. China VEGF Inhibitor Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 49. China VEGF Inhibitor Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 50. Asia VEGF Inhibitor Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 51. Asia VEGF Inhibitor Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 52. Asia VEGF Inhibitor Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 53. Asia VEGF Inhibitor Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 54. Asia VEGF Inhibitor Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 55. Asia VEGF Inhibitor Drugs Market Size by Region (2018-2024) & (US$ Million)
Table 56. Asia VEGF Inhibitor Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 57. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 62. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 64. Pfizer Company Details
Table 65. Pfizer Business Overview
Table 66. Pfizer VEGF Inhibitor Drugs Product
Table 67. Pfizer Revenue in VEGF Inhibitor Drugs Business (2018-2024) & (US$ Million)
Table 68. Pfizer Recent Developments
Table 69. Novartis AG Company Details
Table 70. Novartis AG Business Overview
Table 71. Novartis AG VEGF Inhibitor Drugs Product
Table 72. Novartis AG Revenue in VEGF Inhibitor Drugs Business (2018-2024) & (US$ Million)
Table 73. Novartis AG Recent Developments
Table 74. GlaxoSmithKline plc Company Details
Table 75. GlaxoSmithKline plc Business Overview
Table 76. GlaxoSmithKline plc VEGF Inhibitor Drugs Product
Table 77. GlaxoSmithKline plc Revenue in VEGF Inhibitor Drugs Business (2018-2024) & (US$ Million)
Table 78. GlaxoSmithKline plc Recent Developments
Table 79. Sanofi Company Details
Table 80. Sanofi Business Overview
Table 81. Sanofi VEGF Inhibitor Drugs Product
Table 82. Sanofi Revenue in VEGF Inhibitor Drugs Business (2018-2024) & (US$ Million)
Table 83. Sanofi Recent Developments
Table 84. AstraZeneca plc Company Details
Table 85. AstraZeneca plc Business Overview
Table 86. AstraZeneca plc VEGF Inhibitor Drugs Product
Table 87. AstraZeneca plc Revenue in VEGF Inhibitor Drugs Business (2018-2024) & (US$ Million)
Table 88. AstraZeneca plc Recent Developments
Table 89. Bristol-Myers-Squibb Company Company Details
Table 90. Bristol-Myers-Squibb Company Business Overview
Table 91. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product
Table 92. Bristol-Myers-Squibb Company Revenue in VEGF Inhibitor Drugs Business (2018-2024) & (US$ Million)
Table 93. Bristol-Myers-Squibb Company Recent Developments
Table 94. Genentech, Inc. (Roche) Company Details
Table 95. Genentech, Inc. (Roche) Business Overview
Table 96. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product
Table 97. Genentech, Inc. (Roche) Revenue in VEGF Inhibitor Drugs Business (2018-2024) & (US$ Million)
Table 98. Genentech, Inc. (Roche) Recent Developments
Table 99. Merck & Co., Inc. Company Details
Table 100. Merck & Co., Inc. Business Overview
Table 101. Merck & Co., Inc. VEGF Inhibitor Drugs Product
Table 102. Merck & Co., Inc. Revenue in VEGF Inhibitor Drugs Business (2018-2024) & (US$ Million)
Table 103. Merck & Co., Inc. Recent Developments
Table 104. Bayer AG Company Details
Table 105. Bayer AG Business Overview
Table 106. Bayer AG VEGF Inhibitor Drugs Product
Table 107. Bayer AG Revenue in VEGF Inhibitor Drugs Business (2018-2024) & (US$ Million)
Table 108. Bayer AG Recent Developments
Table 109. Eli Lilly & Company Company Details
Table 110. Eli Lilly & Company Business Overview
Table 111. Eli Lilly & Company VEGF Inhibitor Drugs Product
Table 112. Eli Lilly & Company Revenue in VEGF Inhibitor Drugs Business (2018-2024) & (US$ Million)
Table 113. Eli Lilly & Company Recent Developments
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global VEGF Inhibitor Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global VEGF Inhibitor Drugs Market Share by Type: 2022 VS 2029
Figure 3. Tyrosine Kinase Inhibitors Features
Figure 4. Monoclonal Antibodies Features
Figure 5. Others Features
Figure 6. Global VEGF Inhibitor Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global VEGF Inhibitor Drugs Market Share by Application: 2022 VS 2029
Figure 8. Oncology Case Studies
Figure 9. Ophthalmology Case Studies
Figure 10. Others Case Studies
Figure 11. VEGF Inhibitor Drugs Report Years Considered
Figure 12. Global VEGF Inhibitor Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global VEGF Inhibitor Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global VEGF Inhibitor Drugs Market Share by Region: 2022 VS 2029
Figure 15. Global VEGF Inhibitor Drugs Market Share by Players in 2022
Figure 16. Global Top VEGF Inhibitor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Inhibitor Drugs as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by VEGF Inhibitor Drugs Revenue in 2022
Figure 18. North America VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America VEGF Inhibitor Drugs Market Share by Type (2018-2029)
Figure 20. North America VEGF Inhibitor Drugs Market Share by Application (2018-2029)
Figure 21. North America VEGF Inhibitor Drugs Market Share by Country (2018-2029)
Figure 22. United States VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe VEGF Inhibitor Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 25. Europe VEGF Inhibitor Drugs Market Share by Type (2018-2029)
Figure 26. Europe VEGF Inhibitor Drugs Market Share by Application (2018-2029)
Figure 27. Europe VEGF Inhibitor Drugs Market Share by Country (2018-2029)
Figure 28. Germany VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. China VEGF Inhibitor Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 35. China VEGF Inhibitor Drugs Market Share by Type (2018-2029)
Figure 36. China VEGF Inhibitor Drugs Market Share by Application (2018-2029)
Figure 37. Asia VEGF Inhibitor Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 38. Asia VEGF Inhibitor Drugs Market Share by Type (2018-2029)
Figure 39. Asia VEGF Inhibitor Drugs Market Share by Application (2018-2029)
Figure 40. Asia VEGF Inhibitor Drugs Market Share by Region (2018-2029)
Figure 41. Japan VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. South Korea VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. China Taiwan VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Southeast Asia VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. India VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Australia VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Share by Type (2018-2029)
Figure 49. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Share by Application (2018-2029)
Figure 50. Middle East, Africa, and Latin America VEGF Inhibitor Drugs Market Share by Country (2018-2029)
Figure 51. Brazil VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Mexico VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Turkey VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Israel VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. GCC Countries VEGF Inhibitor Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Pfizer Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2024)
Figure 58. Novartis AG Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2024)
Figure 59. GlaxoSmithKline plc Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2024)
Figure 60. Sanofi Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2024)
Figure 61. AstraZeneca plc Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2024)
Figure 62. Bristol-Myers-Squibb Company Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2024)
Figure 63. Genentech, Inc. (Roche) Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2024)
Figure 64. Merck & Co., Inc. Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2024)
Figure 65. Bayer AG Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2024)
Figure 66. Eli Lilly & Company Revenue Growth Rate in VEGF Inhibitor Drugs Business (2018-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries